Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality8/10

SOPHiA Genet Q3 revenue up 25%, BioPharma partnerships drive growth

Nov 3, 2026, 6:59 AM EST1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Strong YoY revenue growth, narrowing losses, and upper-end 2026 guidance coupled with BioPharma deals should improve investor sentiment and valuation multiple, despite FX headwinds and non-IFRS caveats.

AI summary

What happened, with direct paths to the underlying reporting

SOPHiA GENETICS reported Q3 2026 results with $24.3M in revenue, up 25% YoY, and improving EBITDA metrics as it pursues profitability. The company reaffirmed guidance at the upper end of $94–$96M for 2026, citing strong U.S. demand, 30 new genomics customers, 118% net retention, and notable BioPharma deals, including AstraZeneca CDx collaborations. These factors underscore accelerating multi-geo growth and potential upside into 2027 if FX headwinds subside.

Q3 2026 revenue $24.3M, +25% YoY; gross margin 65.7% (72.8% adj).
Net loss $20.3M; adjusted EBITDA loss $6.1M, improved 31% YoY.
2026 full-year revenue guided to the upper end of $94–96M; FX headwind risk.
30 new core genomics customers in Q3; Net Dollar Retention 118%.
Two AstraZeneca CDx programs; multimodal AI project expands BioPharma footprint.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.